Christine N Spencer Selected Research

Immune Checkpoint Inhibitors

10/2023	Prior anti-CTLA-4 therapy impacts molecular characteristics associated with anti-PD-1 response in advanced melanoma.
1/2023	Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma.
1/2023	T cell immunotherapies engage neutrophils to eliminate tumor antigen escape variants.
1/2022	Hallmarks of Resistance to Immune-Checkpoint Inhibitors.
12/2021	Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response.
1/2021	Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade.
1/2020	Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma.
1/2020	B cells and tertiary lymphoid structures promote immunotherapy response.
12/2018	Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.
12/2018	Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Christine N Spencer Research Topics

Disease

15	Melanoma (Melanoma, Malignant) 04/2024 - 01/2016
14	Neoplasms (Cancer) 10/2023 - 01/2016
2	Disease Progression 01/2018 - 03/2016
1	COVID-19 04/2024
1	Overweight 01/2023
1	Tertiary Lymphoid Structures 01/2020
1	Neoplasm Metastasis (Metastasis) 01/2020
1	Headache (Headaches) 01/2018
1	Fever (Fevers) 01/2018
1	Chills 01/2018
1	Uveal melanoma 01/2017
1	Macular Degeneration (Age-Related Maculopathy) 11/2011

Drug/Important Bio-Agent (IBA)

14	Immune Checkpoint InhibitorsIBA 10/2023 - 01/2016
7	Biomarkers (Surrogate Marker)IBA 04/2024 - 01/2016
2	NivolumabIBA 04/2024 - 11/2018
1	Vancomycin FDA LinkGeneric 04/2024
1	Anti-Bacterial Agents (Antibiotics)IBA 04/2024
1	AntibodiesIBA 10/2023
1	DNA (Deoxyribonucleic Acid)IBA 01/2023
1	CarbonIBA 01/2023
1	Neoplasm Antigens (Tumor Antigens)IBA 01/2023
1	AntigensIBA 01/2023
1	Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA 01/2023
1	Melanoma-Specific AntigensIBA 01/2023
1	Dietary Fiber FDA Link 12/2021
1	IpilimumabIBA 11/2018
1	trametinibIBA 01/2018
1	dabrafenibIBA 01/2018
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2018
1	Retinaldehyde (Retinal)IBA 11/2011

Therapy/Procedure

10	Therapeutics 10/2023 - 01/2016
7	Immunotherapy 01/2023 - 01/2017
3	Precision Medicine 01/2018 - 01/2016